Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Nijmegen Medical Centre, Huispost 630, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Support Care Cancer. 2012 Feb;20(2):319-24. doi: 10.1007/s00520-010-1082-8. Epub 2011 Jan 18.
Depression is highly prevalent in advanced cancer patients, but the diagnosis of depressive disorder in patients with advanced cancer is difficult. Screening instruments could facilitate diagnosing depressive disorder in patients with advanced cancer. The aim of this study was to determine the validity of the Beck Depression Inventory (BDI-II) and a single screening question as screening tools for depressive disorder in advanced cancer patients.
Patients with advanced metastatic disease, visiting the outpatient palliative care department, were asked to fill out a self-questionnaire containing the Beck Depression Inventory (BDI-II) and a single screening question "Are you feeling depressed?" The mood section of the PRIME-MD was used as a gold standard.
Sixty-one patients with advanced metastatic disease were eligible to be included in the study. Complete data were obtained from 46 patients. The area under the curve of the receiver operating characteristics analysis of the BDI-II was 0.82. The optimal cut-off point of the BDI-II was 16 with a sensitivity of 90% and a specificity of 69%. The single screening question showed a sensitivity of 50% and a specificity of 94%.
The BDI-II seems an adequate screening tool for a depressive disorder in advanced cancer patients. The sensitivity of a single screening question is poor.
抑郁症在晚期癌症患者中高发，但在晚期癌症患者中诊断抑郁障碍较为困难。筛查工具可以帮助诊断晚期癌症患者的抑郁障碍。本研究旨在确定贝克抑郁自评量表（BDI-II）和单一筛查问题作为晚期癌症患者抑郁障碍筛查工具的有效性。
患有晚期转移性疾病、在姑息治疗门诊就诊的患者被要求填写一份自我问卷，其中包括贝克抑郁自评量表（BDI-II）和一个单一的筛查问题“您感到沮丧吗？”以 PRIME-MD 的情绪部分作为金标准。
61 名患有晚期转移性疾病的患者符合纳入研究的条件。46 名患者获得了完整的数据。BDI-II 的受试者工作特征曲线下面积为 0.82。BDI-II 的最佳截断点为 16，灵敏度为 90%，特异性为 69%。单一筛查问题的灵敏度为 50%，特异性为 94%。
BDI-II 似乎是晚期癌症患者抑郁障碍的一种合适的筛查工具。单一筛查问题的灵敏度较差。
